Online inquiry

IVTScrip™ mRNA-Human ARGFX, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK25878MR)

This product GTTS-WK25878MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the ARGFX protein. This product can be used in Epiblast cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001012659.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 503582
UniProt ID A6NJG6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARGFX, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WK25878MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK22002MR IVTScrip™ mRNA-Human ARHGAP8, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP8
GTTS-WK16438MR IVTScrip™ mRNA-Human ANKS3, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ANKS3
GTTS-WK24777MR IVTScrip™ mRNA-Human ARRDC1, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARRDC1
GTTS-WK25102MR IVTScrip™ mRNA-Human ASCC1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASCC1
GTTS-WK21989MR IVTScrip™ mRNA-Human ARHGAP24, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP24
GTTS-WK8930MR IVTScrip™ mRNA-Human Additional GABA Compounds, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Additional GABA Compounds
GTTS-WK7580MR IVTScrip™ mRNA-Human ABLIM3, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABLIM3
GTTS-WK26812MR IVTScrip™ mRNA-Human ARHGEF19, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF19
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW